Efficacy News and Research

RSS

New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer

New Colombia Resources, Inc., a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with the Phoenix Tears Foundation for the research and development of a cannabis based medicine to treat skin cancer in Colombia.

9 May 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Mice study shows specific energy source responsible for performing complex cognitive functions

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others.

9 May 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disorder).

8 May 2014

Finding has implications for understanding cognitive decline in degenerative diseases

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others. The finding has implications for understanding the cognitive decline seen in aging and degenerative diseases such as Alzheimer's and multiple sclerosis.

8 May 2014

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

8 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.

8 May 2014

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

A selection of health policy stories from California, New York, Connecticut, Georgia, Indiana and North Carolina.

8 May 2014

BIOTRONIK's Entovis pacemaker system gets FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration has granted approval for its Entovis pacemaker system with ProMRI technology.

7 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

Air, surface sampling techniques used by US government effective in fighting bioterrorism, says study

Air and surface sampling techniques currently used by the US government are effective in fighting bioterrorism and potentially saving lives, a Saint Louis University researcher finds.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

New research focuses on using wheat fiber to lower cholesterol and prevent development of heart disease

The saying, "we are what we eat," has never been more true. Nutritionists increasingly emphasize that the nutrients in the foods we consume can potentially create health and reduce disease.

7 May 2014

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

With rates of Clostridium difficile (C. difficile) now rivaling drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA) as the most common bacteria to cause healthcare-associated infections, new expert guidance encourages healthcare institutions to implement and prioritize prevention efforts for this infectious diarrhea.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.

6 May 2014

Laparoscopic-assisted colonoscopy with polypectomy reduces hospital utilization

A surgical method combining two techniques for removing precancerous polyps during colonoscopies can substantially reduce the recovery time and the length of hospital stays, potentially saving the health-care system millions of dollars, according to research presented today at Digestive Disease Week- (DDW).

6 May 2014

Efficacy News and Research

New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Mice study shows specific energy source responsible for performing complex cognitive functions

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Finding has implications for understanding cognitive decline in degenerative diseases

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

BIOTRONIK's Entovis pacemaker system gets FDA approval

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Air, surface sampling techniques used by US government effective in fighting bioterrorism, says study

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New research focuses on using wheat fiber to lower cholesterol and prevent development of heart disease

New expert guidance encourages healthcare institutions to implement prevention efforts infectious diarrhea

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Naurex's two lead antidepressant programs achieve major milestones

Laparoscopic-assisted colonoscopy with polypectomy reduces hospital utilization

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News